FDA Warns Mylan Over Quality Concerns At India Facility
Violations included a failure to “thoroughly investigate” unexplained discrepancies in drug batches and “missing, deleted, and lost data."
fda warn mylan quality concerns india facility violations include failure thoroughly investigate unexplained discrepancy drug batch missing delete lose datum